US3934034A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hydroxy substituted diphenylalkyls for treatment of lipidemia
Assignee: Sandoz Inc
•
Filing: 1973-08-09
•
Granted: 1976-01-20
•
Expires: 1993-08-09
Abstract
Abstract Certain hydroxy diphenylalkyls, e.g., nordihydroguairetic acid, are useful as hypolipidemic agents.
Inventors
- 👤 Robert E. Manning
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 02:50
CPC Classifications
C; C07; C07C; C07C39/00; C07C39/12; C07C39/15
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
119 words
A method for treating lipidemia, which comprises orally administering to a mammal in need of said treatment an anti-hyperlipidemic effective amount of a compound of the formula: ##SPC2## where m is 0, 1 or 2; n is 0 or 1; R 1 represents hydrogen or hydroxy; and R 2 and R 3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and that when m is 1 or 2, n is 1 and R 1 is hydroxy and that when m is 2 each R 2 can be the same or different and each R 3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Claim 2
Independent Claim
119 words
A method for treating lipidemia, which comprises orally administering to a mammal in need of said treatment an anti-hyperlipidemic effective amount of a compound of the formula: ##SPC2## where m is 0, 1 or 2; n is 0 or 1; R 1 represents hydrogen or hydroxy; and R 2 and R 3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and that when m is 1 or 2, n is 1 and R 1 is hydroxy and that when m is 2 each R 2 can be the same or different and each R 3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Claim 3
Dependent Claim
24 words
The method according to claim 1 wherein the compound is administered at a daily dose of from about 150 milligrams to about 2000 milligrams.
Claim 4
Dependent Claim
34 words
The method according to claim 1 wherein the compound is administered in a unit dosage form comprising said compound to the extent of from about 37.5 milligrams to about 1000 milligrams per unit dosage.
Claim 5
Dependent Claim
13 words
The method according to claim 1 in which the compound is nordihydroguairetic acid.
Claim 6
Dependent Claim
12 words
The method according to claim 1 in which the compound is bis(p-hydroxyphenyl)methane.
Claim 7
Dependent Claim
59 words
A method for treating lipidemia, which comprises orally administering to a mammal in need of said treatment an antihyperlipidemic effective amount of a compound of the formula ##SPC3## in pharmaceutically acceptable alkali or alkaline earth metal salt form, where m, n, R 1 , R 2 , R 3 and the proviso are as set out in claim 10.
Claim 8
Dependent Claim
24 words
The method according to claim 6 wherein the compound is administered at a daily dose of from about 600 milligrams to about 4000 milligrams.
Claim 9
Dependent Claim
34 words
The method according to claim 6 wherein the compound is administered in a unit dosage form comprising said compound to the extent of from about 300 milligrams to about 2000 milligrams per unit dosage.
Claim 10
Dependent Claim
14 words
The method according to claim 6 in which the compound is disodium bis (p-hydroxyphenyl)methane.
Claim 11
Dependent Claim
44 words
A pharmaceutical composition in solid form useful in the treatment of lipidemia in mammals comprising bis(p-hydroxyphenyl) methane as the active ingredient thereof, and a pharmaceutically acceptable carrier therefore, said active ingredient being present in said composition from about 150 milligrams to about 4000 milligrams.
Claim 12
Dependent Claim
44 words
A pharmaceutical composition in solid form useful in the treatment of lipidemia in mammals comprising bis(p-hydroxyphenyl) methane as the active ingredient thereof, and a pharmaceutically acceptable carrier therefore, said active ingredient being present in said composition from about 150 milligrams to about 4000 milligrams.
Claim 13
Dependent Claim
23 words
The pharmaceutical composition of claim 10, wherein said active ingredient is present in said composition from about 150 milligrams to about 2000 milligrams.
Claim 14
Dependent Claim
23 words
The pharmaceutical composition of claim 11, wherein said active ingredient is present in said composition from about 37.5 milligrams to about 1000 milligrams.
Claim 15
Dependent Claim
30 words
The composition according to claim 11, wherein said carrier is a solid orally ingestible carrier and the active ingredient is present in said composition from about 50 to 250 milligrams.
Claim 16
Dependent Claim
36 words
The pharmaceutical composition according to claim 10, wherein said active ingredient is in the form of a pharmaceutically acceptable alkali or alkaline earth metal salt and is present from about 600 milligrams to about 4000 milligrams.
Claim 17
Dependent Claim
23 words
The pharmaceutical composition of claim 14, wherein said active ingredient is present in said composition from about 150 milligrams to about 2000 milligrams.
Claim 18
Dependent Claim
43 words
The composition according to claim 10, wherein said carrier is a solid orally ingestible carrier and the active ingredient is in the form of a pharmaceutically acceptable alkali or alkaline earth metal salt and is present in said composition from about 300 milligrams.
Claim 19
Dependent Claim
12 words
A composition according to claim 10, in the form of a tablet.
Claim 20
Dependent Claim
15 words
The composition according to claim 14 in which the active ingredient is disodium bis (p-hydroxyphenyl)methane.
Claim 21
Dependent Claim
38 words
A tablet useful in the treatment of lipidemia in mammals comprising bis(p-hydroxyphenyl) methane as the active ingredient thereof and a pharmaceutically acceptable carrier therefor, said active ingredient being present in said tablet from about 50 to 250 milligrams.
Claim 22
Dependent Claim
38 words
A tablet useful in the treatment of lipidemia in mammals comprising bis(p-hydroxyphenyl) methane as the active ingredient thereof and a pharmaceutically acceptable carrier therefor, said active ingredient being present in said tablet from about 50 to 250 milligrams.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-01-19 | 1979-07-21 | 1980-01-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-01-19 | 1983-07-21 | 1984-01-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-01-19 | 1987-07-21 | 1988-01-20 | $7700.00 | Window Closed / Lapsed |